Dicerna Pharmaceuticals Inc. (DRNA) said that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), in connection with Novo Nordisk's cash tender offer for Dicerna expired on December 24, 2021.
Unless the tender offer is extended, the offer and withdrawal rights will expire on December 27, 2021.
On November 18, 2021, Dicerna agreed to be acquired by Novo Nordisk A/S (NVO) for $38.25 per share in cash. The purchase price represented a total equity value of $3.3 billion and a premium of 80% to Dicerna's closing price on November 17, 2021.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.